Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | POLD1 | P28340 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753931 | 0.89 | POLG (0.44) | POLGP2RY2P2RY4P2RY6ENPP1 | |
| SCHEMBL25753580 | 0.89 | POLG (0.44) | POLGP2RY2P2RY4P2RY6ENPP1 | |
| SCHEMBL25753563 | 0.89 | ENTPD1 (0.38) | P2RX1P2RX3P2RX4ENTPD1 | |
| SCHEMBL25753564 | 0.88 | POLB (0.41) | P2RY2P2RY4P2RY6POLBPOLA1 | |
| SCHEMBL22327080 | 0.83 | POLG (0.44) | POLGP2RY2P2RY4P2RY6ENPP1 | |
| SCHEMBL22327216 | 0.83 | POLG (0.44) | POLGP2RY2P2RY4P2RY6ENPP1 | |
| SCHEMBL22327076 | 0.83 | POLG (0.44) | POLGP2RY2P2RY4P2RY6ENPP1 | |
| SCHEMBL25753565 | 0.81 | POLB (0.36) | P2RY2P2RY4P2RY6POLBPOLA1 | |
| SCHEMBL25753926 | 0.80 | ENTPD1 (0.39) | P2RX1P2RX3P2RX4ENTPD1 | |
| SCHEMBL25753576 | 0.80 | ENTPD1 (0.39) | P2RX1P2RX3P2RX4ENTPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | POLG 89/4885P2RY2 1336/4885P2RY4 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.